12 results on '"GHILENCEA, LIVIU NICOLAE"'
Search Results
2. Management of the Two-Week Wait Pathway for Skin Cancer Patients, before and during the Pandemic: Is Virtual Consultation an Option?
- Author
-
Chiru, Maria-Roxana, Hindocha, Sandip, Burova, Ekaterina, Bejan, Gabriel-Cristian, Manea, Laura-Maria, and Ghilencea, Liviu-Nicolae
- Subjects
SKIN cancer ,TELEMEDICINE ,PANDEMICS ,CANCER patients ,BASAL cell carcinoma ,MELANOMA ,SQUAMOUS cell carcinoma - Abstract
Background: Although telemedicine emerged more than 100 years ago, the recent pandemic underlined the role of remote assessment of different diseases. The diagnoses of cutaneous conditions, especially malignant lesions, have placed significant stress on the fast-track pathway for general practitioners (GPs), dermatologists, and plastic surgeons. The aim of the study was to compare (pre- and during the pandemic) the ability of professionals to face the challenge. Methods: The study was composed of 1943 consecutive patients (mean age 61.9 ± 18.3, 53.8% female) assessed by GPs, face-to-face (988 patients, 50.8%, between October 2019 and March 2020) and by virtual (video/photo) visits (955 patients, 49.2%, between March 2020 and October 2020) for skin lesions, and referred to secondary care via the two-week wait pathway for suspected skin malignancy. Results: The two groups had similar primary skin malignancies identification rates (24.3% vs. 22.1%, p = 0.25). The virtual visits identified squamous cell carcinoma (SCC) better than face-to-face consultations (p = 0.04), but identified basal cell carcinoma less-well (BCC, p = 0.02), whereas malignant melanoma (MM) was equally identified in the two groups (p = 0.13). There was no difference in the median breach time (days) of the two-week wait pathway (12, IQR = 6 vs. 12, IQR = 5, p = 0.16) in the two groups. Virtual assessments (by GPs) of skin lesions suspected of malignancy, and referred via the two-week wait pathway, increased the probability of diagnosing SCC by 42.9% (p = 0.03), while for malignant melanomas, face-to-face and virtual consultations were alike (p = 0.12). Conclusions: The equivalent outcomes in the management of skin cancers (SCC, MM) via the two-week pathway through virtual consultations and face-to-face appointments underline the role of telemedicine as a reliable alternative to face-to-face assessments. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. B-Type Natriuretic Peptide at Admission Is a Predictor of All-Cause Mortality at One Year after the First Acute Episode of New-Onset Heart Failure with Preserved Ejection Fraction.
- Author
-
Ghilencea, Liviu-Nicolae, Bejan, Gabriel-Cristian, Zamfirescu, Marilena-Brîndusa, Stănescu, Ana Maria Alexandra, Matei, Lavinia-Lucia, Manea, Laura-Maria, Kilic, Ismail Dogu, Bălănescu, Serban-Mihai, Popescu, Andreea-Catarina, and Myerson, Saul Gareth
- Subjects
- *
MORTALITY , *VENTRICULAR ejection fraction , *HOSPITAL mortality , *HEART failure , *PROPORTIONAL hazards models , *GLOMERULAR filtration rate - Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) has been assessed extensively, but few studies analysed the predictive value of the NT-proBNP in patients with de novo and acute HFpEF. We sought to identify NT-proBNP at admission as a predictor for all-cause mortality and rehospitalisation at 12 months in patients with new-onset HFpEF. Methods: We analysed 91 patients (73 ± 11 years, 68% females) admitted for de novo and acute HFpEF, using the Cox proportional hazard risk model. Results: An admission NT-proBNP level above the threshold of 2910 pg/mL identified increased all-cause mortality at 12 months (AUC = 0.72, sensitivity = 92%, specificity = 53%, p < 0.001). All-cause mortality adjusted for age, gender, medical history, and medication in the augmented NT-proBNP group was 16-fold higher (p = 0.018), but with no difference in rehospitalisation rates (p = 0.391). The predictors of increased NT-proBNP ≥ 2910 pg/mL were: age (p = 0.016), estimated glomerular filtration rate (p = 0.006), left atrial volume index (p = 0.001), history of atrial fibrillation (p = 0.006), and TAPSE (p = 0.009). Conclusions: NT-proBNP above 2910 pg/mL at admission for de novo and acute HFpEF predicted a 16-fold increased mortality at 12 months, whereas values less than 2910 pg/mL forecast a high likelihood of survival (99.3%) in the next 12 months, and should be considered as a useful prognostic tool, in addition to its utility in diagnosing heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Functional tests in patients with ischemic heart disease.
- Author
-
Avram, Rodica Lucia, Nechita, Alexandru Cristian, Popescu, Marius Nicolae, Teodorescu, Matei, Ghilencea, Liviu-Nicolae, Turcu, Diana, Lechea, Elena, Maher, Sean, Bejan, Gabriel Cristian, and Berteanu, Mihai
- Subjects
CORONARY disease ,MYOCARDIAL ischemia ,CARDIAC patients ,OLDER people ,WALKING speed - Abstract
Lately, easier and shorter tests have been used in the functional evaluation of cardiac patients. Among these, walking speed (WS) and Timed Up and Go (TUG) tests are associated with all-cause mortality, mainly cardiovascular and the rate of re-hospitalization, especially in the elderly population. We prospectively analyzed a group of 38 patients admitted to the Cardiology Clinic from Elias Hospital, Romania, with chronic coronary syndrome (CCS) (n=22) and STEMI (n=16). We assessed the patients immediately after admission and before discharge with G-WALK between the 1st and 30th of September 2019. Our study group had a mean age of 62.7±12.1 years. Patients with a low WS were older (69.90±12.84 vs. 59.90±10.32 years, p=0.02) and had a lower serum hemoglobin (12.38±1.20 vs. 13.72±2.07 g/dl, p=0.02). The WS significantly improved during hospitalization (p=0.03) after optimal treatment. The TUG test performed at the time of admission had a longer duration in patients with heart failure (14.05 vs. 10.80 sec, p=0.02) and was influenced by patients' age (r=0.567, p=0.02), serum creatinine (r=0.409, p=0.03) and dilation of right heart chambers (r=0.399, p=0.03). WS and TUG tests can be used in patients with CCS and STEMI, and are mainly influenced by age, thus having a greater value among the elderly. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Predictors of Atrial Fibrillation Recurrences after a First Radiofrequency Catheter Ablation Intervention for Paroxysmal Atrial Fibrillation—Experience of a Low Volume Ablation Centre.
- Author
-
Matei, Lavinia-Lucia, Silişte, Călin, Stoica, Sebastian, Bejan, Gabriel-Cristian, Ghilencea, Liviu-Nicolae, and Vinereanu, Dragoş
- Subjects
ATRIAL fibrillation ,DISEASE relapse ,CATHETER ablation ,ELECTROCARDIOGRAPHY ,PALPITATION - Abstract
Background and Objectives: Atrial fibrillation recurrences (AFR) after radiofrequency catheter ablation (RFCA) are not uncommon, up to 65% of patients having relapses in the first year. However, current data are based mainly on studies from centres with a large volume of ablations, as they include technically inhomogeneous interventions, and populations with different types of AF. The aim of our study was to assess and stratify the risk at 6 and 12 months for AFR after a single RFCA, in patients with paroxysmal AF, in a centre with low volume activity. Materials and Methods: We enrolled 40 patients who underwent an initial RFCA, followed by continuous 48 h ECG monitoring at 1, 3, 6, and 12 months. Patients self-monitored their cardiac activity by random daily radial pulse palpation or in the presence of palpitations. Results: Ten independent predictors for late AFR were identified, and a 6-month risk score was computed using three of them: AFR duration in the first month, number of AFR between 1 and 3 months, and supraventricular ectopics per 24 h at 6 months. The score can explain 59% of the AFR (p = 0.001). A further 12-month assessment identified three independent predictors. The presence of AFR between 6–12 months is the most important of them (OR = 23.11, 95% CI = 3.87–137.83, p = 0.001), explaining 45% of AFR over 1 year. The risk scores at 6 and 12 months were internally validated. Conclusions: The 6-month score proved to be a useful tool in guiding further strategy for patients with a low risk, while a longer follow-up to 12 months may avoid unnecessary early reinterventions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Minimum Left Atrial Volume Evaluated by 3D Echocardiography Predicts Atrial Fibrillation Recurrences After a First Radiofrequency Catheter Ablation for Paroxysmal Episodes.
- Author
-
MATEI, Lavinia-Lucia, GHILENCEA, Liviu-Nicolae, BEJAN, Gabriel-Cristian, STOICA, Sebastian, DRAGOI-GALRINHO, Ruxandra, SILISTE, Calin, and VINEREANU, Dragos
- Subjects
- *
CATHETER ablation , *ATRIAL fibrillation , *LEFT heart atrium , *ECHOCARDIOGRAPHY , *PROGNOSIS , *RADIO frequency therapy - Abstract
Background: Atrial fibrillation (AF) is facilitated by an enlarged left atrium (LA) and increased LA mass. Left atrium volume (LAV) has a powerful prognostic value for sinus rhythm (SR) maintenance. Persistent SR may lead to atrial reverse-remodeling; therefore, preprocedural LAV may predict the outcome after AF radiofrequency catheter ablation (RFCA). Study aim: To evaluate the relationship between LA dimensions and AF recurrences (AFR) using echocardiography. Methods: We enrolled 40 patients (56 ± 10 years; 73% males) who underwent a first RFCA for paroxysmal AF. Bi- (2DE) and three-dimensional (3DE) echocardiography was performed prior to RFCA and at 12-months follow-up. Rhythm control was monitored for up to two years after the intervention by periodic ECG Holter monitoring. Results: Atrial fibrillation recurrences were recorded in 21 patients (52%) in the first year after RCFA. The only predictor of outcome from pre-ablation LA parameters was 3DE minimum LAVi (p = 0.042), that explained 21.4% of AF recurrences in the first year, with a cut-off value of 21.29 mL/m². The mean 3DE min LAVi was 24.29 ± 8.01 mL/m² and patients without AFR in the first year had a lower LAVi than those with AFR (20.92 ± 6.19 mL/m² vs. 27.25 ± 8.43 mL/m², p=0.028). One year after RFCA, a decrease in medio-lateral, superior-inferior diameters and volumes were recorded in AF free patients. Eleven patients (27%) had AF recurrences after the first year and LAV 12-months after RFCA were found to be predictors of long-term outcome, with minimum LAVi as the strongest predictor of recurrences (p=0.014), explaining 36% of episodes, with a cut-off over 22.49 mL/m². Conclusion: Radiofrequency ablation controls LA remodeling in patients with clinical success in terms of AF freedom. Left atrium 3DE volumetry is accurate in predicting RFCA outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. EFFECTS OF NEUROMUSCULAR ELECTRICAL STIMULATION IN PATIENTS WITH ACUTE HEART FAILURE -- RESULTS OF A SINGLE-CENTER RANDOMIZED TRIAL.
- Author
-
AVRAM, RODICA LUCIA, NECHITA, ALEXANDRU CRISTIAN, POPESCU, MARIUS NICOLAE, TEODORESCU, MATEI, GHILENCEA, LIVIU NICOLAE, TURCU, DIANA, and BERTEANU, MIHAI
- Subjects
HEART failure patients ,EXERCISE tolerance ,GROUP psychotherapy ,VENTRICULAR ejection fraction ,QUADRICEPS muscle ,TREATMENT duration - Abstract
Objective: We evaluated the effects of neuromuscular electrical stimulation (NMES) therapy on functional capacity and oxidative stress in patients hospitalized for acute heart failure (AHF). Design: We included 30 consecutive patients admitted for AHF with a left ventricular ejection fraction ≤ 50% who were randomized into two groups: NMES therapy added on conventional rehabilitation (CR) (n = 15, 67.2 ±13.35 years) and CR alone (n = 15, 63.26 ± 10.29 years). NMES therapy was performed at the level of the quadriceps muscle bilaterally, daily, for 60 minutes with a frequency of 10 Hz. Results: The mean duration of NMES therapy was 6.93 ± 2.54 days. Functional capacity assessed by the 6 minute walk test was significantly improved in the group with NMES therapy (p=0.036). The oxidized LDL value showed a decreasing trend compared to the admission value in the group with NMES therapy, but without statistical significance. Conclusion: This paper shows that for patients with AHF, NMES therapy used for a short term and initiated early during the hospitalization period improves exercise tolerance, suggesting the importance and possible necessity of including it as standard cardiac recovery therapy. NMES did not influence the plasmatic value of oxidized LDL. [ABSTRACT FROM AUTHOR]
- Published
- 2020
8. An observational, prospective study of the pharmacoinvasive strategy approach to ST-segment myocardial infarction (STEMI) in the era of primary percutaneous coronary intervention based on Elias Heart Centre Interventional Registry (EIRE Study). The Southern Romanian experience
- Author
-
Ghilencea, Liviu-Nicolae, Popescu, Andreea-Catarina, Dimulescu, Doina, Maher, Sean, Al Hassan, Ali, Linte, Adrian, Stanca, Ionut, Melnic, Mihai, Barsan, Sergiu, Bejan, Cristian, Arama, Laura, Zamfirescu, Brandusa, Petrea, Stefanita, Gîrgel, Cristian, Roamba, Maria-Lorena, Huidu, Simona, Ionescu, Luminita, Aflorii, Raluca, Rachieru, Andreea, and Marinescu, Maria
- Subjects
- *
PERCUTANEOUS coronary intervention , *MYOCARDIAL infarction , *LONGITUDINAL method , *THROMBOLYTIC therapy , *HOSPITAL mortality - Abstract
Aims - The objective of our study is to compare pharmaco-invasive strategy (PhIS) in terms of safety and efficacy, with primary percutaneous coronary intervention (pPCI) strategy as standard therapy for STEMI patients from remote areas. Background - At present, primary percutaneous coronary intervention (pPCI) is the preferred reperfusion strategy for STEMI patients. However, despite pPCI being the gold standard, it is not always achievable due to variables such as lack of cardiac catheterization services and delays in the first medical contact-to-balloon time. Methods - This observational study is based on a prospective analysis of a cohort of 157 patients with ST-elevation myocardial infarction, over nine months, at Elias University Hospital (EUH). The study assessed the safety and efficacy of a sequence of fibrinolytic therapy in the first contact hospital before being referred to our center for PCI (PhIS, 35 patients, 22.29%) versus angioplasty alone (pPCI, 122 patients, 77.70%) during hospitalization. The primary outcomes studied were in-hospital death, and major adverse cardiac events (MACE), while secondary outcomes were the length of in-hospital stay, and the safety of the procedure. Results - The median reperfusion time was lower for the PhIS group compared to the primary PCI group (4 hours, IQR:6.25 vs 7 hours, IQR:12.38, p<0.05). The left ventricular systolic function (%) on arrival at EUH was higher in the PhIS group compared with the PCI alone group (46.55; 95%CI 42.42-49.15 vs 41.73; 95%CI 39.91-43.34; p=0.04). The mean number of diseased vessels, including the culprit-lesion, were similar in the two groups (2.84 vs 2.82, p=0.09). The in-hospital mortality rate was lower in the PhIS group than in the primary PCI group (1 patient; 2.9% vs 18 patients; 14.80%; p=0.05), while the number of in-hospital major adverse cardiac events (MACE) was not significantly different (17.10% vs 26.20%; p=0.27). There was no difference of the median length of hospitalization (6 days, IQR:2 vs 5 days, IQR:3; p=0.67) for the PhIS, and primary PCI groups, respectively. The safety endpoints of the procedures were similar in the two groups. Conclusions - Pharmaco-invasive strategy (PhIS) had clinical and procedural outcomes (in-hospital MACE, length of in-hospital stay) similar to primary percutaneous coronary intervention (pPCI), in case of long distances to catheterization laboratories. Efficient thrombolysis makes PhIS a viable alternative in saving lives with a lower rate of in-hospital death than pPCI. Performed thrombolysis in a local non-PCI center and referral of the STEMI patients to a 24/7 catheterization laboratory may be a good option for areas where the infrastructure of such facilities is weak. [ABSTRACT FROM AUTHOR]
- Published
- 2019
9. A Practical Risk Score for Prediction of Early Readmission after a First Episode of Acute Heart Failure with Preserved Ejection Fraction.
- Author
-
Zamfirescu, Marilena-Brîndușa, Ghilencea, Liviu Nicolae, Popescu, Mihaela-Roxana, Bejan, Gabriel Cristian, Ghiordanescu, Ileana Maria, Popescu, Andreea-Catarina, Myerson, Saul G., Dorobanțu, Maria, and Gladysheva, Inna P.
- Subjects
- *
PATIENT readmissions , *HEART failure , *GLOMERULAR filtration rate , *EPIDERMAL growth factor receptors - Abstract
Background: The first admission for acute heart failure with preserved ejection fraction (HFpEF) drastically influences the short-term prognosis. Baseline characteristics may predict repeat hospitalization or death in these patients. Methods: A 103 patient-cohort, admitted for the first acute HFpEF episode, was monitored for six months. Baseline characteristics were recorded and their relation to the primary outcome of heart failure readmission (HFR) and secondary outcome of all-cause mortality was assessed. Results: We identified six independent determinants for HFR: estimated glomerular filtration rate (eGFR) (p = 0.07), hemoglobin (p = 0.04), left ventricle end-diastolic diameter (LVEDD) (p = 0.07), E/e' ratio (p = 0.004), left ventricle outflow tract velocity-time integral (LVOT VTI) (p = 0.045), and diabetes mellitus (p = 0.06). Three of the variables were used to generate a risk score for HFR: LVEDD, E/e', LVOT VTI -DEI Score = − 28.763 + 4.558 × log (LVEDD (mm)) + 1.961 × log (E/e' ratio) + 1.759 × log (LVOT VTI (cm)). Our model predicts a relative amount of 20.50% of HFR during the first 6 months after the first acute hospitalization within the general population with HFpEF with a DEI Score over −0.747. Conclusions: We have identified three echocardiographic parameters (LVEDD, E/e', and LVOT VTI) that predict HFR following an initial acute HFpEF hospitalization. The prognostic DEI score demonstrated good accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention
- Author
-
Sara Abou Sherif, Carlo Di Mario, Gianluca Caiazzo, Enrico Fabris, Ismail Dogu Kilic, Elvin Kedhi, Liviu-Nicolae Ghilencea, Kilic, Ismail Dogu, Fabris, Enrico, Kedhi, Elvin, Ghilencea, Liviu-Nicolae, Caiazzo, Gianluca, Sherif, Sara Abou, and Di Mario, Carlo
- Subjects
Drug ,medicine.medical_specialty ,media_common.quotation_subject ,Coronary atherosclerosi ,Disease ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Protease Inhibitors ,030212 general & internal medicine ,Intensive care medicine ,Coronary atherosclerosis ,Vulnerable plaque ,Intra-coronary imaging ,Ultrasonography, Interventional ,media_common ,Angiology ,Coronary Heart Disease (S Virani and S Naderi, Section Editors) ,business.industry ,Secondary prevention ,Cholesterol, HDL ,PCSK9 Inhibitors ,medicine.disease ,Plaque, Atherosclerotic ,Blood Component Removal ,Therapeutic Lifestyle Changes ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business ,Preclinical imaging - Abstract
Purpose of Review Patients diagnosed with coronary artery disease are at a high risk of subsequent cardiovascular events; therefore, secondary prevention in the form of therapeutic lifestyle changes, and drug therapies is vital. This article aims to review potential application of intra-coronary imaging for the evaluation of plaque modifications, induced by medications for secondary prevention for CAD. Recent Findings Intra-coronary imaging provides detailed information on the atherosclerotic plaque which is the primary pathological substrate for the recurrent ischemic cardiovascular events. These modalities can detect features associated with high risk and allow serial in vivo imaging of lesions. Therefore, intravascular imaging tools have been used in landmark studies and played a role in improving our understanding of the disease processes. Summary Changes in size and plaque composition over time can be evaluated by these tools and may help understanding the impact of a treatment. Moreover, surrogate imaging end points can be used when testing new drugs for secondary prevention.
- Published
- 2020
11. Telemedicine: Benefits for Cardiovascular Patients in the COVID-19 Era.
- Author
-
Ghilencea LN, Chiru MR, Stolcova M, Spiridon G, Manea LM, Stănescu AA, Bokhari A, Kilic ID, Secco GG, Foin N, and Di Mario C
- Abstract
The recent pandemic with SARS-CoV-2 raises questions worldwide regarding telemedicine for housebound patients, including those with cardiovascular conditions. The need for further investigation, monitoring and therapeutic management are advancing practical issues which had not been identified for consideration prior to the pandemic. Using the marketing assessment, we identified the needs of the patients and evaluated the future steps necessary in the short term to meet them. The research found progress made via telemedicine in monitoring and conducting minor decisions (like up-titrating the doses of different medication regimens) in patients with several cardiovascular diseases (heart failure, atrial fibrillation, high blood pressure), as there is a worldwide trend to develop new telemonitoring biosensors and devices based on implantable delivered transcatheter. The worldwide telemedicine trend encourages a switch from small and hesitating steps to a more consistent assessment of the patients, based on high technology and Interventional Cardiology. Cardiovascular telemedicine, although made a sustainable effort in managing patients' health, has many obstacles to overcome before meeting all their needs. Data security, confidentiality and reimbursement are the top priorities in developing remote Cardiology. The regulatory institutions need to play an integrative role in leading the way for defining the framework of future telemedicine activities. The SARS-CoV-2 outbreak with all its tragedy served to reinforce the message that telemedicine services can be life-saving for cardiovascular patients. Once the Covid-19 era will fade away, telemedicine is likely to remain a complementary service of standard care. There is still room to improve the remote identification and investigation of heart disease, provide an accurate diagnosis and therapeutic regimen, and update regulations and guidelines to the new realities of technological progress in the field., Competing Interests: L-NG is a Consultant in Cardiology at the Elias University Hospital in Bucharest, and a Lecturer at the Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. He also graduated International Economic Relations at the Academy of Economic Sciences in Bucharest with a degree in World Economy. He completed his training in Cardiology at hospitals in Birmingham and Oxford, and was subject of several honorary fellowships in Interventional Cardiology at Royal Brompton Hospital in London, UK, under the supervision of CDM. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Ghilencea, Chiru, Stolcova, Spiridon, Manea, Stănescu, Bokhari, Kilic, Secco, Foin and Di Mario.)
- Published
- 2022
- Full Text
- View/download PDF
12. The E/e' Ratio-Role in Risk Stratification of Acute Heart Failure with Preserved Ejection Fraction.
- Author
-
Zamfirescu MB, Ghilencea LN, Popescu MR, Bejan GC, Maher SM, Popescu AC, and Dorobanțu M
- Subjects
- Echocardiography, Humans, Prognosis, Risk Assessment, Stroke Volume, Ventricular Function, Left, Heart Failure
- Abstract
Background and Objectives : Heart failure with preserved ejection fraction (HFpEF) remains a worldwide management problem. Although there is a general effort for characterizing this population, few studies have assessed the predictive value of the echocardiographic E/e' ratio in patients with acute HFpEF. The aim of the study was to identify groups with different prognosis in patients hospitalized with a first acute episode of HFpEF. Materials and Methods : The primary endpoint of the study was heart failure readmissions (HFR) at 6 months, while the secondary outcome was six-month mortality. We consecutively enrolled 91 patients hospitalized for the first time with acute HFpEF. We examined the E/e' ratio as an independent predictor for HFR using univariate regression. Results : We identified and validated the E/e' ratio as an independent predictor for HFR. An E/e' ratio threshold value of 13.80 was calculated [(area under the receiver operating characteristic curve (AUROC) = 0.693, sensitivity = 78.60%, specificity = 55%, p < 0.004)] and validated as an inflection point for an increased number of HFR. Thus, we divided the study cohort into two groups: group 1 with an E/e' ratio < 13.80 (n = 39) and group 2 with an E/e' ratio > 13.80 (n = 49). Compared to group 1, group 2 had an increased number of HFR ( p = 0.003) and a shorter time to first HFR ( p = 0.002). However, this parameter did not influence all-cause mortality within six months ( p = 0.84). Conclusions : The dimensionless E/e' ratio is a useful discriminator between patients with acute HFpEF. An E/e' value over 13.80 represents a simple, yet effective instrument for assessing the HFR risk. However, all-cause mortality at six months is not influenced by the E/e' ratio.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.